Hong Gong-Zebger
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 30, 2026
Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 07, 2025
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 17, 2025
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: March 14, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 06, 2025
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 23, 2024
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 07, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 16, 2023
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2023
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
Journal: EClinicalMedicine
Published: October 17, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026